Literature DB >> 25964312

Dasatinib in recurrent glioblastoma: failure as a teacher.

David Schiff1, Jann Sarkaria1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25964312      PMCID: PMC5762007          DOI: 10.1093/neuonc/nov086

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  15 in total

Review 1.  A renaissance for SRC.

Authors:  Timothy J Yeatman
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

Review 2.  Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.

Authors:  Susan M Chang; Kathleen R Lamborn; John G Kuhn; W K Alfred Yung; Mark R Gilbert; Patrick Y Wen; Howard A Fine; Minesh P Mehta; Lisa M DeAngelis; Frank S Lieberman; Timothy F Cloughesy; H Ian Robins; Lauren E Abrey; Michael D Prados
Journal:  Neuro Oncol       Date:  2008-06-17       Impact factor: 12.300

3.  Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

Authors:  Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Patricia L Dahia; Yanfeng Wang; Bin Peng; Lauren E Abrey; Jeffrey Raizer; Timothy F Cloughesy; Karen Fink; Mark Gilbert; Susan Chang; Larry Junck; David Schiff; Frank Lieberman; Howard A Fine; Minesh Mehta; H Ian Robins; Lisa M DeAngelis; Morris D Groves; Vinay K Puduvalli; Victor Levin; Charles Conrad; Elizabeth A Maher; Kenneth Aldape; Michael Hayes; Laurie Letvak; Merrill J Egorin; Renaud Capdeville; Richard Kaplan; Anthony J Murgo; Charles Stiles; Michael D Prados
Journal:  Clin Cancer Res       Date:  2006-08-15       Impact factor: 12.531

Review 4.  Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.

Authors:  Siyuan Zhang; Dihua Yu
Journal:  Trends Pharmacol Sci       Date:  2011-12-09       Impact factor: 14.819

5.  Active efflux of Dasatinib from the brain limits efficacy against murine glioblastoma: broad implications for the clinical use of molecularly targeted agents.

Authors:  Sagar Agarwal; Rajendar K Mittapalli; David M Zellmer; Jose L Gallardo; Randy Donelson; Charlie Seiler; Stacy A Decker; Karen S Santacruz; Jenny L Pokorny; Jann N Sarkaria; William F Elmquist; John R Ohlfest
Journal:  Mol Cancer Ther       Date:  2012-08-13       Impact factor: 6.261

Review 6.  Targeting SRC in glioblastoma tumors and brain metastases: rationale and preclinical studies.

Authors:  Manmeet S Ahluwalia; John de Groot; Wei Michael Liu; Candece L Gladson
Journal:  Cancer Lett       Date:  2010-12-08       Impact factor: 8.679

Review 7.  Src kinases as therapeutic targets for cancer.

Authors:  Lori C Kim; Lanxi Song; Eric B Haura
Journal:  Nat Rev Clin Oncol       Date:  2009-10       Impact factor: 66.675

8.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

Authors:  Kimmo Porkka; Perttu Koskenvesa; Tuija Lundán; Johanna Rimpiläinen; Satu Mustjoki; Richard Smykla; Robert Wild; Roger Luo; Montserrat Arnan; Benoit Brethon; Lydia Eccersley; Henrik Hjorth-Hansen; Martin Höglund; Hana Klamova; Håvar Knutsen; Suhag Parikh; Emmanuel Raffoux; Franz Gruber; Finella Brito-Babapulle; Hervé Dombret; Rafael F Duarte; Erkki Elonen; Ron Paquette; C Michel Zwaan; Francis Y F Lee
Journal:  Blood       Date:  2008-05-13       Impact factor: 22.113

Review 9.  Src signaling in cancer invasion.

Authors:  Marcello Guarino
Journal:  J Cell Physiol       Date:  2010-04       Impact factor: 6.384

10.  Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.

Authors:  Jinyan Du; Paula Bernasconi; Karl R Clauser; D R Mani; Stephen P Finn; Rameen Beroukhim; Melissa Burns; Bina Julian; Xiao P Peng; Haley Hieronymus; Rebecca L Maglathlin; Timothy A Lewis; Linda M Liau; Phioanh Nghiemphu; Ingo K Mellinghoff; David N Louis; Massimo Loda; Steven A Carr; Andrew L Kung; Todd R Golub
Journal:  Nat Biotechnol       Date:  2008-12-21       Impact factor: 54.908

View more
  17 in total

1.  A Near-IR Fluorescent Dasatinib Derivative That Localizes in Cancer Cells.

Authors:  Syed Muhammad Usama; Bosheng Zhao; Kevin Burgess
Journal:  Bioconjug Chem       Date:  2019-04-01       Impact factor: 4.774

2.  KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.

Authors:  Michael J Ciesielski; Yahao Bu; Stephan A Munich; Paola Teegarden; Michael P Smolinski; James L Clements; Johnson Y N Lau; David G Hangauer; Robert A Fenstermaker
Journal:  J Neurooncol       Date:  2018-09-20       Impact factor: 4.130

3.  Cell Lineage-Based Stratification for Glioblastoma.

Authors:  Zilai Wang; Daochun Sun; Yu-Jung Chen; Xuanhua Xie; Yufeng Shi; Viviane Tabar; Cameron W Brennan; Tejus A Bale; Chenura D Jayewickreme; Dan R Laks; Sheila Alcantara Llaguno; Luis F Parada
Journal:  Cancer Cell       Date:  2020-07-09       Impact factor: 31.743

Review 4.  Investigational new drugs for brain cancer.

Authors:  Verena Staedtke; Ren-Yuan Bai; John Laterra
Journal:  Expert Opin Investig Drugs       Date:  2016-05-17       Impact factor: 6.206

5.  Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model.

Authors:  Rupa Juthani; Brian Madajewski; Barney Yoo; Ulrich Wiesner; Michelle S Bradbury; Cameron W Brennan; Li Zhang; Pei-Ming Chen; Feng Chen; Melik Z Turker; Kai Ma; Michael Overholtzer; Valerie A Longo; Sean Carlin; Virginia Aragon-Sanabria; Jason Huse; Mithat Gonen; Pat Zanzonico; Charles M Rudin
Journal:  Clin Cancer Res       Date:  2019-09-12       Impact factor: 12.531

6.  Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma.

Authors:  Miriam Ratliff; Hichul Kim; Hao Qi; Minsung Kim; Bosung Ku; Daniel Dominguez Azorin; David Hausmann; Rajiv K Khajuria; Areeba Patel; Elena Maier; Loic Cousin; Arnaud Ogier; Felix Sahm; Nima Etminan; Lukas Bunse; Frank Winkler; Victoria El-Khoury; Michael Platten; Yong-Jun Kwon
Journal:  Int J Mol Sci       Date:  2022-06-12       Impact factor: 6.208

Review 7.  Inhibitors of Src Family Kinases, Inducible Nitric Oxide Synthase, and NADPH Oxidase as Potential CNS Drug Targets for Neurological Diseases.

Authors:  Meghan C Gage; Thimmasettappa Thippeswamy
Journal:  CNS Drugs       Date:  2021-01-30       Impact factor: 5.749

8.  Mining Drug-Target Associations in Cancer: Analysis of Gene Expression and Drug Activity Correlations.

Authors:  Monica M Arroyo; Alberto Berral-González; Santiago Bueno-Fortes; Diego Alonso-López; Javier De Las Rivas
Journal:  Biomolecules       Date:  2020-04-25

9.  A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma.

Authors:  Obada T Alhalabi; Michael N C Fletcher; Thomas Hielscher; Tobias Kessler; Tolga Lokumcu; Ulrich Baumgartner; Elena Wittmann; Silja Schlue; Mona Göttmann; Shaman Rahman; Ling Hai; Lea Hansen-Palmus; Laura Puccio; Ichiro Nakano; Christel Herold-Mende; Bryan W Day; Wolfgang Wick; Felix Sahm; Emma Phillips; Violaine Goidts
Journal:  Neuro Oncol       Date:  2022-01-05       Impact factor: 13.029

Review 10.  SRC Kinase in Glioblastoma News from an Old Acquaintance.

Authors:  Claudia Cirotti; Claudia Contadini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2020-06-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.